Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cancer Genetics Inc (CGIX)
Cancer Genetics Inc (CGIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment...

CGIX : 4.61 (-2.33%)
Cancer Genetics to Present at the Annual 33rd ROTH Conference

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...

CGIX : 4.61 (-2.33%)
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm

INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm NEW YORK, NY / ACCESSWIRE / February 4, 2021 / Halper Sadeh LLP, a global investor...

RP : 88.72 (+0.08%)
PRGX : 7.71 (+0.13%)
NK : 32.49 (+14.89%)
CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)

Barchart Exclusives

Marathon Oil's High FCF Yield Makes Its Covered Call and Short Put Yields Are Attractive
Marathon Oil reported consistent free cash flow giving it a 14.8% FCF yield, putting MRO stock on a 1.8% dividend yield. This makes covered call and short-put options attractive in close expiry periods. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar